echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The first half performance of large variety enterprises of traditional Chinese medicine injections declined significantly and the growth momentum was worrying

    The first half performance of large variety enterprises of traditional Chinese medicine injections declined significantly and the growth momentum was worrying

    • Last Update: 2018-09-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [China Pharmaceutical network industry trends] the release of the report card of pharmaceutical enterprises in the first half of 2018 has basically ended Although the performance of Chinese patent medicine enterprises has a good momentum of growth, the performance of traditional Chinese medicine injection enterprises is not satisfactory The author has learned that, from the perspective of the representative Chinese medicine injection enterprises in China, despite the growth of business income and net profit of individual enterprises, the vast majority of enterprises have seen a significant decline in business income compared with the same period last year Some insiders said that the decline of traditional Chinese medicine injection will continue to expand in the future, among which the obvious one is that the market of traditional Chinese medicine injection originally used for children or infected patients has shrunk, and it is expected to reach 35% in 2018 Experts said that the industry policy will continue to tighten in the future, and suggested that enterprises relying on traditional Chinese medicine injection transform as soon as possible Step pharmaceutical's net profit growth rate is -0.06% and its operating revenue growth rate is 5.57% In the first half of the year, step pharmaceutical's total operating revenue is 5.748 billion yuan and its net profit is 715 million yuan, with a net interest rate of 12.44% in the first half of the year Step pharmaceutical promotes the industrialization and modernization of traditional Chinese medicine with innovation As mentioned above, a series of institutional changes and policy implementation have brought challenges to the pharmaceutical industry in the short term Affected by policy restrictions, the whole traditional Chinese medicine injection industry is currently in a painful period of development In the first half of the year, the performance of step pharmaceutical was also greatly influenced by the traditional Chinese medicine injection industry In the first half of 2018, Lizhu group achieved revenue of 4.564 billion yuan, a year-on-year increase of 6.78%; the net profit attributable to shareholders of listed companies was 633 million yuan, a year-on-year increase of 25.66%; the net profit attributable to shareholders of listed companies after deducting non recurring profit and loss was 571 million yuan, a year-on-year increase of 25.45% During the reporting period, the revenue growth of the four business segments of the company's western medicine preparation, traditional Chinese medicine preparation, API, diagnostic reagent and equipment was + 14.18%, - 20.52%, + 19.49% and + 16.90% respectively Although the net profit income and operating income have increased, the overall gross profit margin has decreased by 2.27%, which is mainly due to the decline in the income of traditional Chinese medicine preparations with high gross profit margin Kunyao group's net profit growth rate is - 15.34% and its business income growth rate is 23.99% In the first half of 2018, kunyao group's business income proportion of traditional Chinese medicine injections dropped to 25%, "the main reason is that in February 2017, the new version of the medical insurance catalogue, the company's leading product Xuesaitong freeze-dried powder injection needle was listed in the scope of restricted use in hospitals above level II, and the sales volume of this product decreased by 26.13%." Yin Zhongchen, general manager of Kunming Pharmaceutical Group business department, said that the pressure of "drug proportion" and product safety concerns made many hospitals above the second level reluctant to open traditional Chinese medicine injection Kunming Pharmaceutical Group said that enterprises will pay equal attention to imitation, creation and maintenance in the next step, and gradually promote the transformation of the company to an innovative enterprise During the reporting period, Yibai pharmaceutical achieved an operating revenue of 1892703800 yuan, a year-on-year decrease of 59184400 yuan, or 3.03% Among them, the company's medical industry segment achieved sales revenue of 147026300 yuan, a year-on-year decrease of 121.5603 million yuan, a year-on-year decrease of 7.64%; the medical service segment revenue was 422036000 yuan, a year-on-year increase of 62.8692 million yuan, an increase of 17.50% Yibai pharmaceutical said in the semi annual business review report that in the aspect of traditional Chinese medicine injection, due to the limitation of detection technology and detection method, the composition and mechanism of action of traditional Chinese medicine injection are not clear enough, and there are some problems such as complex composition, unclear degree and poor stability of injection In addition, the origin, harvest time, processing method, processing technology, storage and storage of traditional Chinese medicine injection The quality of traditional Chinese medicine is also greatly affected by the As consumers pay great attention to product safety and quality, if there are product quality or safety problems, it will have a great impact on the reputation and product sales of the enterprise, and may also bring some legal risks to the enterprise.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.